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Introduc<on	  
	  
•  Hypertension	  is	  the	  most	  common	  
cardiovascular	  disease	  found	  in	  individuals	  
recreaYng	  at	  high	  alYtudes.1	  	  
•  Evidence	  is	  conflicYng	  on	  how	  blood	  
pressure	  (BP)	  changes	  with	  alYtude	  in	  
hypertensive	  (HTN)	  and	  normotensive	  
(NTN)	  individuals.	  
	  
•  Most	  studies	  are	  done	  at	  alYtudes	  <3500m	  
using	  small	  numbers	  of	  subjects.2	  
	  
•  In	  NTNs,	  acute	  hypoxia	  causes	  increased,	  
decreased,	  or	  unchanged	  BP;	  in	  HTNs,	  BP	  	  
may	  increase	  and	  then	  gradually	  decline.2	  	  
	  
•  Evidence	  for	  efficacy	  of	  BP	  medicaYon	  at	  
alYtude	  is	  limited.	  
•  There	  is	  no	  evidence	  ACEIs	  effecYvely	  
control	  BP	  in	  HTNs	  at	  alYtude.	  
•  ARBs	  control	  BP	  <3400m	  but	  does	  not	  at	  
higher	  elevaYons	  in	  NTNs.3	  
•  SelecYve	  and	  non-­‐selecYve	  β-­‐blockers	  blunt	  
rising	  BP	  in	  NTNs	  traveling	  to	  alYtude.4,5	  
Objec<ves	  
	  
•  Determine	  how	  BP	  changes	  in	  HTN	  and	  NTN	  
trekkers	  at	  alYtude.	  	  
•  Determine	  effecYveness	  of	  anYhypertensive	  




•  This	  study	  was	  a	  prospecYve,	  observaYonal	  
cohort	  carried	  out	  in	  the	  Khumbu	  Valley	  of	  
Nepal,	  en	  route	  to	  Everest	  Base	  Camp.	  
October-­‐November	  2014.	  
	  
•  Demographics,	  anthropometrics,	  medical	  
history	  and	  medicaYon	  use	  was	  gathered.	  	  
	  
•  Manual	  BP	  was	  measured	  in	  the	  same	  arm	  at	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Severe	  Hypertension	  (>180/100)	  Found	  	  
Most	  Frequently	  in	  HTN	  Trekkers	  Across	  Al<tudes	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•  BP	  change	  with	  alYtude	  is	  variable	  in	  individual	  trekkers;	  decreased	  BP	  with	  ascent	  is	  more	  likely	  in	  HTN	  trekkers	  
than	  NTN	  trekkers,	  but	  demographic	  and	  anthropometric	  differences	  may	  exist	  between	  the	  cohorts.	  	  
	  
•  Severe	  hypertension	  is	  more	  common	  in	  HTN	  trekkers	  than	  NTN	  trekkers	  but	  was	  asymptomaYc	  in	  all	  cases.	  
	  
•  Subjects	  on	  ACEIs	  and	  thiazides	  were	  more	  likely	  to	  have	  severe	  hypertension	  than	  those	  on	  other	  medicaYons.	  
	  
•  Further	  study	  is	  required	  to	  determine	  the	  clinical	  importance	  of	  these	  findings.	  
	  
	  
HTN	   NTN	  
Gender	   M	  =	  43	  	  	  F	  =	  17	   M	  =	  346	  	  	  F	  =	  257	  
Age	  (years)	   58	   47	  
BMI	   25	   24	  
Al<tude	   HTN	  (n=60)	   NTN	  (n=604)	  
2800m	   58	   601	  
3400m	   42	   479	  
4400m	   25	   335	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